Upstate Active Clinical Trials
Study Title:
ACNS1723 - A Phase 2 Study of Dabrafenib (NSC#763760) with Trametinib (NSC#763093) after Local Irradiation in Newly DiagnosedBRAFv600 - Mutant High-Grade Glioma (HGG) (IND #145355)
What is the purpose of the study? (in Layman's terms, please describe the study)
Study for newly diagnosed High-grade glioma with BRAFv600 mutant tumorsUpstate Institutional Review Board (IRB) Number:
1510386Study/Protocol ID:
ACNS1723Study Phase:
IIPatient Age Group:
ChildrenPrincipal Investigator:
Melanie A ComitoWho is eligible?
< or = 25 years of ageWhat is involved if I participate?
- How long is the study?
2 years - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
No - What tests and procedures are involved?
Standard of care study
Where will the study take place?
Cancer centerOther Information:
NoneWho can I contact for more information?
Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]